Table 4.
PSA response rate, overall survival, and time-to-treatment failure
| Outcome | C20 | C25 | Statistic | |||
|---|---|---|---|---|---|---|
| N | Response rate, n (%) | N | Response rate, n (%) | OR (95% CI) | p | |
| PSA response | 601 | 169 (28.1)b | ||||
| Unadjusted | 177 | 49 (27.7) | 146 | 46 (31.5) | 1.20 (0.74–1.94) | 0.453 |
| Multivariablea | 135 | 38 (28.2) | 120 | 36 (30.0) | 1.18 (0.66–2.13) | 0.572 |
| PSM | 106 | 28 (26.4) | 103 | 33 (32.0) | 1.31 (0.72–2.39) | 0.372 |
| Outcome | N | Median (95% CI) | N | Median (95% CI) | HR (95% CI) | p |
| OS (days) | 656 | 319 (293–361)b | ||||
| Unadjusted | 188 | 287 (240–326) | 159 | NR | 0.71 (0.53–0.97) | 0.030 |
| Multivariablea | 141 | 287 (234–327) | 129 | NR | 0.69 (0.48–0.99) | 0.047 |
| PSM | 110 | 291 (230–NR) | 112 | NR | 0.73 (0.50–1.08) | 0.119 |
| TTF (days) | 660 | 116 (108–135)b | ||||
| Unadjusted | 190 | 113 (94–137) | 159 | 120 (104–157) | 0.78 (0.62–0.97) | 0.026 |
| Multivariablea | 143 | 115 (92–138) | 129 | 115 (99–157) | 0.71 (0.54–0.93) | 0.014 |
| PSM | 112 | 122 (90–148) | 112 | 120 (109–158) | 0.75 (0.57–0.99) | 0.046 |
C20 20 mg/m2 cabazitaxel, C25 25 mg/m2 cabazitaxel, PSA Prostate-specific antigen, OR Odds ratio, CI Confidence interval, PSM Propensity score matching, HR Hazard ratio, OS Overall survival, NR Not reached, TTF Time-to-treatment failure
aCovariates were: age, body surface area, duration of disease, Gleason score, TNM, performance status, PSA, medical history, complications, curative intent focal therapy, palliative radiation therapy, and previous treatment (docetaxel, enzalutamide or abiraterone acetate)
bIn all available patients